- Home
- MYNZ vs DRCT Comparison
MYNZ vs DRCT Comparison
Compare MYNZ & DRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYNZ
- DRCT
- Stock Information
- Founded
- MYNZ 2021
- DRCT 2018
- Country
- MYNZ Germany
- DRCT United States
- Employees
- MYNZ N/A
- DRCT N/A
- Industry
- MYNZ Biotechnology: Pharmaceutical Preparations
- DRCT Computer Software: Programming Data Processing
- Sector
- MYNZ Health Care
- DRCT Technology
- Exchange
- MYNZ Nasdaq
- DRCT Nasdaq
- Market Cap
- MYNZ 7.9M
- DRCT 9.2M
- IPO Year
- MYNZ 2021
- DRCT 2022
- Fundamental
- Price
- MYNZ $1.77
- DRCT $0.41
- Analyst Decision
- MYNZ Buy
- DRCT Strong Buy
- Analyst Count
- MYNZ 2
- DRCT 1
- Target Price
- MYNZ $14.00
- DRCT $6.00
- AVG Volume (30 Days)
- MYNZ 180.5K
- DRCT 764.8K
- Earning Date
- MYNZ 08-26-2025
- DRCT 08-05-2025
- Dividend Yield
- MYNZ N/A
- DRCT N/A
- EPS Growth
- MYNZ N/A
- DRCT N/A
- EPS
- MYNZ N/A
- DRCT N/A
- Revenue
- MYNZ $893,991.00
- DRCT $36,459,000.00
- Revenue This Year
- MYNZ $26.06
- DRCT $50.71
- Revenue Next Year
- MYNZ $4.97
- DRCT $26.31
- P/E Ratio
- MYNZ N/A
- DRCT N/A
- Revenue Growth
- MYNZ N/A
- DRCT N/A
- 52 Week Low
- MYNZ $1.30
- DRCT $0.38
- 52 Week High
- MYNZ $18.40
- DRCT $6.59
- Technical
- Relative Strength Index (RSI)
- MYNZ 53.56
- DRCT 37.46
- Support Level
- MYNZ $1.41
- DRCT $0.38
- Resistance Level
- MYNZ $1.76
- DRCT $0.47
- Average True Range (ATR)
- MYNZ 0.16
- DRCT 0.07
- MACD
- MYNZ 0.02
- DRCT -0.01
- Stochastic Oscillator
- MYNZ 68.12
- DRCT 7.41
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
About DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.